Skip to main content

Table 1 Demographic and clinical characteristics and treatment modalities in patients with Brucella arhtritis

From: Diagnostic role of inflammatory markers in pediatric Brucella arthritis

Clinical features Mean ± SD, median range or number (%) (n:64)
Mean age (month) 92.3 ± 41.2
Gender
 Male 34 (53.1)
 Female 30 (46.9)
Duration of hospitalization (day) 6 (2–76)
Symptoms and clinical findings
 Arthralgia 64 (100)
 Joint pain 61 (95.3)
 Fever 55 (85.9)
 Myalgia 49 (76.6)
 Anorexia 46 (71.9)
 Weakness 40 (62.5)
 Shivering 39 (60.9)
 Restriction of movement 36 (56.2)
 Diaphoresis 33 (51.6)
 Swelling 22 (34.3)
 Increase temperature on joint 22 (34.3)
 Joint redness 22 (34.3)
 Headache 20 (31.3)
 Abdominal pain 14 (21.9)
 Joint effusion 13 (20.3)
 Chest pain 11 (17.2)
 Neck pain 2 (3.1)
Joint involvement
 Ankle 34 (53.1)
 Knee 30 (46.9)
Laboratory findings
 Erythrocyte sedimentation rate (mm/h) 40.9 ± 20.4
 C-reactive protein (mg/L) 28.1 ± 22.4
Brucella hemagglutination test
 160 10 (15.8)
 320 25 (39.1)
 ≥640 29 (45.3)
Positive culture
 Blood 4 (6.3)
 Joint puncture 4 (6.3)
 Blood + Joint puncture 5 (7.9)
Treatment
 Rifampicin + Tetracycline + Streptomycin 13 (20.3)
 Rifampicin + Tetracycline + Gentamicin 14 (21.8)
 Rifampicin + TMP-SMX + Gentamicin 37 (57.8)
  1. TMP-SMX trimethoprim-sulfamethoxazole, SD standard deviation